Small molecule inhibitors of Aβ-aggregation and neurotoxicity

Hawkes, Cheryl A. and Ng, Vivian and McLaurin, Joanne (2009) Small molecule inhibitors of Aβ-aggregation and neurotoxicity. Drug Development Research, 70 (2). pp. 111-124. ISSN 0272-4391

Full text not available from this repository.


Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of Aβ peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the effects of chronic Aβ production and are not a secondary pathological effect caused by a distant trigger; therefore targeting Aβ is a viable pursuit. In this review, we will discuss the various small molecule anti- aggregation inhibitors that have been reported in the literature, with emphasis on compounds that are presently being investigated in clinical trials.

Item Type:
Journal Article
Journal or Publication Title:
Drug Development Research
Uncontrolled Keywords:
ID Code:
Deposited By:
Deposited On:
04 Oct 2019 15:15
Last Modified:
22 Nov 2022 08:09